BioSpace News Archive

- Patients with locally advanced or metastatic solid tumors are being enrolled and dosed with SRK-181 in combination with anti-PD-(L)1 therapy in Part A2 of the DRAGON Phase 1 clinical trial - An update on Part A dose escalation is expected in the fourth quarter of 2020; Part B efficacy and safety data from the trial anticipated starting in 2021

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced today the appointment of Dr. Kenneth Anderson and Dr. Asher Chanan-Khan to its Board of Directors subject to shareholder approval. “Drs. Anderson and Chanan-Khan are world leading scientists in hematology. They represent a strong addition to our Board of Directors and will hel

Bio-Path Holdings, Inc. announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:30 a.m. ET.

Agile Therapeutics, Inc., a forward-thinking women’s healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Wednesday, September 16, 2020 at 11:30 a.m. EDT.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 10:30 a.m. Eastern Time.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has received trademark registration from the Japan Patent Office (“JPO”) for the Company’s use of HONEDRA® as the brand name for CLBS12,

Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings

DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has appointed former Medtronic Spine and Biologics finance executive, Jeff Poole, as its first Chief Financial Officer (CFO).

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday 15th September at 3:30-3:50 PM (EDT).

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri.